Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$38.50 USD
+0.52 (1.36%)
Updated Apr 22, 2024 11:54 AM ET
After-Market: $38.82 +0.33 (0.84%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CLDX 38.50 +0.52(1.36%)
Will CLDX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CLDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLDX
Down -14.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
All You Need to Know About Celldex (CLDX) Rating Upgrade to Buy
CLDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -17.39% in 4 Weeks, Here's Why You Should You Buy the Dip in Celldex (CLDX)
Does Celldex (CLDX) Have the Potential to Rally 71.82% as Wall Street Analysts Expect?
Celldex (CLDX) Upgraded to Buy: What Does It Mean for the Stock?
Other News for CLDX
Celldex’s Barzolvolimab Shows Promise for Urticaria Treatment: A Strong Buy Recommendation
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Celldex announces completion of enrollment in Phase 2 study of barzolvolimab
Jasper Therapeutics initiated with bullish view at Evercore ISI, here's why
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call